PakMediNet - Medical Information Gateway of Pakistan
MEDICAL EVENTS Research Guidelines Drug Index Search Literature Support PakMediNet Become our Member Log In Menu ☰

Discussion Forum For Health Professionals

Post a Message

Lost your password?

Post Icon:

Note: Only Health Care Professionals (Doctors, Nurses, Pharmacists etc) and Members of this forum can add a message or reply to this message. Messages of the Non Health Care Professionals will be deleted without notification.

Topic Review - Newest First (only newest 5 are displayed)

aftabac

HCV treatment through miRNA

GlaxoSmithKline (GSK) has established a collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection. Although a clinical development candidate has yet to be identified, recent findings in non-human primates indicate that targeting microRNA-122 blocks HCV replication and could offer advantages over current HCV therapies (Science 327, 198–201; 2010).

Best regards
aftab